Cardinal Health (NYSE:CAH) Issues FY 2025 Earnings Guidance

Cardinal Health (NYSE:CAH) issued an update on its FY 2025 earnings guidance on Friday morning. The company provided earnings per share (EPS) guidance of 7.900-7.900 for the period, compared to the consensus estimate of 8.720. The company issued revenue guidance of -.

Cardinal Health Trading Down 0.6 %

Shares of CAH stock traded down $0.76 on Friday, reaching $126.27. 1,642,944 shares of the stock were exchanged, compared to its average volume of 2,121,686. Cardinal Health has a twelve month low of $93.17 and a twelve month high of $127.27. The company has a market capitalization of $30.56 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 1.48 and a beta of 0.63. The business’s 50 day moving average price is $120.63 and its 200 day moving average price is $111.61.

Cardinal Health (NYSE:CAH) last issued its quarterly earnings data on Friday, November 1st. The company reported $1.88 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.26. Cardinal Health had a net margin of 0.56% and a negative return on equity of 56.56%. The business had revenue of $52.28 billion during the quarter, compared to the consensus estimate of $50.90 billion. During the same quarter in the previous year, the firm earned $1.73 EPS. The company’s revenue was down 4.3% compared to the same quarter last year. Equities research analysts forecast that Cardinal Health will post 7.82 earnings per share for the current year.

Cardinal Health Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd were issued a $0.5056 dividend. This represents a $2.02 annualized dividend and a dividend yield of 1.60%. The ex-dividend date was Thursday, January 2nd. Cardinal Health’s payout ratio is currently 39.30%.

Analysts Set New Price Targets

CAH has been the subject of a number of research reports. Bank of America upgraded Cardinal Health from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $132.00 to $145.00 in a research note on Monday, January 6th. Barclays upped their price target on shares of Cardinal Health from $117.00 to $133.00 and gave the company an “overweight” rating in a research report on Monday, November 4th. UBS Group increased their price target on shares of Cardinal Health from $134.00 to $139.00 and gave the stock a “buy” rating in a research note on Monday, November 4th. TD Cowen upgraded shares of Cardinal Health from a “hold” rating to a “buy” rating and lifted their price objective for the company from $130.00 to $144.00 in a research note on Wednesday, January 8th. Finally, Morgan Stanley increased their target price on shares of Cardinal Health from $127.00 to $136.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Four analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $133.29.

About Cardinal Health

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.